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Background/Aims: As the optimal stereotactic body radiation therapy (SBRT) modality 
for hepatocellular carcinoma (HCC) has not been confirmed, we aimed herein to provide a 
practical guideline by our retrospective review. 
Methods: Thirty-nine patients with primary HCC who underwent liver SBRT via 3 modalities 
(helical tomotherapy [HT]: 22, volumetric modulated arc therapy [VMAT]: 13, Cyberknife: 4) 
at our institution between July 2014 and July 2015 were included. Modalities were compared 
with regard to dose conformity index (CI), homogeneity index (HI), clinical results, and patient 
compliance.
Results: VMAT SBRT had favorable conformity (CI: 0.7±0.2), homogeneity (HI: 1.1±0.0), and 
shortest treatment time (100.2±26.1 seconds). HT SBRT yielded good dosimetric outcomes, 
especially in conformity (CI: 1.0±0.2). Although the Cyberknife SBRT synchrony system allowed 
real-time tumor targeting, the treatment time was longest (3,015.0±447.3 seconds), invasive 
pre-treatment procedures were required, and the HI (1.3±0.0) was lowest. 
Conclusions: All 3 modalities yielded competent dosimetric planning parameters. VMAT 
SBRT was most appropriate for tumors with residual lipiodol or patients with poor conditions. 
HT SBRT is available for multiple or irregular targets. Cyberknife SBRT is recommended for 
carefully selected patients and tumors indicated for sono-guided fiducial insertion.   
(J Liver Cancer 2017;17:45-53)
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INTRODUCTION 
Resection, ablation, and liver transplantation are the avail-
able curative options for hepatocellular carcinoma (HCC), 
according to many clinical practice guidelines. However, only 
10–20% of patients with HCC have resectable tumors1,2; here, 
potentially curative options such as radiofrequency ablation 
(RFA), transarterial chemoembolization (TACE), transarteri-
al chemoinfusion (TACI), or radiotherapy should be consid-
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ered for locoregional tumor control rather than other system-
ic therapies or supportive care. In particular, radiotherapy is 
one of effective locoregional therapies. Although radiotherapy 
is not a standard treatment in the Barcelona Clinic Liver Can-
cer (BCLC) staging system,3,4 the National Comprehensive 
Cancer Network (NCCN) guideline, a major pillar of onco-
logic practice, recommends radiotherapy as a preferred op-
tion.5 
Radiotherapy has recently gained popularity because of 
substantial local antitumor effects.6 In particular, stereotactic 
body radiotherapy (SBRT) has become an important option 
for selected patients ineligible for RFA or TACE who have 
unresectable hepatic lesions measuring <5 cm and good liver 
function.7,8 Accumulating evidence indicates that SBRT may 
be effective for hepatic tumors, with a satisfactory local con-
trol rate and tolerable toxicity profiles in both retrospective9-16 
and prospective17-20 settings. Recently, local control rates of 
80–100% have been demonstrated with SBRT using volumet-
ric modulated arc therapy (VMAT) or Cyberknife.11,12,14,16,19 
Our institution is the first to study SBRT using helical tomo-
therapy (HT) for hepatic tumors and has achieved good re-
sponse rates since 2006. 
SBRT utilizes sophisticated treatment planning, special pa-
tient immobilization devices, and precise image guidance to 
deliver high radiation doses to tumors in 1–5 fractions. SBRT 
can be performed using 3-dimensional conformal radiothera-
py techniques (3D-CRTs) or intensity modulated radiation 
therapy (IMRT) with VMAT, HT, or Cyberknife. Each mo-
dality has been studied regarding SBRT competence and is 
considered effective, with strengths and weaknesses. Many 
studies compared performances of various SBRT modalities 
from clinical and dosimetric viewpoints.21,22 However, such 
comparison studies have been limited in HCC. In current 
HCC clinical practice, SBRT is mainly used as salvage treat-
ment after RFA or TACE failure, rather than primary treat-
ment; HCC-specific clinical consideration is thus required. 
Our institution makes available several precise radiothera-
py systems, including HT, VMAT, and Cyberknife. Although 
these modalities have been proven effective for liver tumor 
SBRT, there is a growing need to select optimal modalities 
depending on clinical situations. Herein, we aimed to provide 
a practical guideline regarding the optimal modality in a cer-
tain situation retrospectively based on our experiences with 
dosimetric parameters, clinical applications, and patient com-
pliance.
METHODS 
1. Patient data
Thirty-nine patients with primary HCC treated via liver 
SBRT in our institution between July 2014 and July 2015 were 
selected as follows: HT SBRT, 22 patients (T group); VMAT 
SBRT, 13 (V group); Cyberknife SBRT, 4 patients (C group). 
Patients’ characteristics are shown in Table 1. 
All patients had Child–Pugh scores of A or B (≤7). Only 1 
patient had lung metastasis; no others had extrahepatic me-
tastasis. All but 1 patient had no vascular tumor thrombosis. 
Most patients (n=37, 95%) received other treatment before 
SBRT and were referred to our department for salvage treat-
ment even after several treatment sessions. Twenty T group 
patients who received initial curative radiotherapy for newly 
diagnosed HCC experienced TACE or TACI failure. Twelve 
V group patients (except 1 with postoperative S1 recurrence) 
received SBRT after TACE or TACI failure. At the time of 
SBRT, residual lipiodol was detected via cone-beam comput-
erized tomography (CT) in 55% (n=12) of T group, 77% 
(n=10) of V group, and 25% (n=1) of C group patients. Re-
garding tumor location, 36% (n=14) of tumors were located 
in S8 (S8 [n=14, 36%] > S4 [n=8, 21%] > S7 [n=7, 18%] > S1 
[n=6, 15%]). Few tumors were located in S2 (n=1, 3%), S3 
(n=2, 5%), or S6 (n=0) (Table 2). 
2. Treatment planning
All patients underwent planning CT (slice thickness = 
3-mm) while immobilized in the supine position with a respi-
ration control device. To correct respiration-related deforma-
tion and rotation of the normal liver and tumor, all patients 
underwent 4-dimensional (4D)-CT scans (SOMATOM Sen-
sation; Siemens, Munich, Germany), in which CT data were 
acquired synchronously with a respiratory signal. For SBRT 
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using HT or VMAT, a customized Vac-LockTM (CIVCO, 
Coralville, IA, USA) was used for patient immobilization; an 
abdominal compressor was used to maintain shallow breath-
ing during treatment. Occasionally, moderate deep-inspira-
tion breath holding with an active breathing control (ABC) 
device replaced the abdominal compressor (applicable only 
with VMAT SBRT). In Cyberknife SBRT, the customized 
Vac-LockTM was used alone because of long treatment time; 
breathing synchronization with fiducial tracking was used. 
A radiation oncologist with expertise in liver tumors con-
toured gross tumor volumes (GTVs) on each slice after fusing 
CT images with dynamic CT and magnetic resonance (MR) 
images. GTV contours were superimposed using 4D-CT se-
ries to generate the internal target volume (ITV); the clinical 
target volume (CTV) was defined as ITV + 5–7 mm. No ad-
ditional margin was added for a planning target volume 
(PTV). Patients were prescribed 56 Gy for PTV and 60 Gy for 
ITV in 4 fractions (≥95% coverage). Cyberknife SBRT did 
not use an ITV; only 60 Gy in 4 fractions was prescribed for a 
single target (PTV). All patients rested for 1 day after every 4 
consecutive treatment fractions. Normal structures and or-
gans at risk (OARs), including remaining normal liver, stom-
ach, duodenum, bowel, kidney, and spinal cord, were also 
contoured. Dose constraints were defined according to the 
Table 1. Patients’ characteristics 
Characteristics
HT 
(n=22) (n, %)
VMAT 
(n=13) (n, %)
Cyberknife 
(n=4) (n, %)
Age (years)
Median 64 
(42-86)
Median 63 
(47-75)
Median 59.5 
(54-72)
Sex
Male 16 (73) 12 (92) 2 (50)
Female 6 (27) 1 (8) 2 (50)
ECOG
0 16 (73) 4 (31) 1 (25)
1 6 (27) 9 (69) 3 (75)
2 0 (0) 0 (0) 0 (0)
Underlying liver 
disease
HBV 13 (59) 8 (62) 3 (75)
HCV 5 (23) 3 (23) 1 (25)
Alcohol-related 1 (4) 2 (15) 0 (0)
None 3 (14) 0 (0) 0 (0)
CTP score
5 20 (91) 9 (69) 3 (75)
6 2 (9) 3 (23) 0 (0)
7 0 (0) 1 (8) 1 (25)
UICC stage
I 1 (4) 0 (0) 0 (0)
II 8 (36) 4 (31) 1 (25)
III 12 (55) 7 (54) 2 (50)
IVA 1 (5) 2 (15) 0 (0)
IVB 0 (0) 0 (0) 1 (25)
Tumor location
S1 3 3
S2 1
S3 1 1
S4 4 3 1
S5 1
S6
S7 6 1
S8 7 6 1
Maximum tumor 
diameter (cm)
Median 2.1  
(0.7-4.8)
Median 1.2  
(0.3-4.8)
Median 2.6  
(1.3-5.5)
Tumor vascular 
thrombosis
Yes 0 (0) 1 (8) 0 (0)
No 22 (100) 12 (92) 4 (100)
Extrahepatic metastasis
Yes 0 (0) 0 (0) 1 (25)
No 22 (100) 13 (100) 3 (75)
Table 1. Continued
Characteristics
HT 
(n=22) (n, %)
VMAT 
(n=13) (n, %)
Cyberknife 
(n=4) (n, %)
Previous treatments
None 2 0 0
Surgery 4 3 0
TACE/TACI 20 12 4
RFA 1 2 2
Sorafenib 0 0 1
Chemotherapy 4 0 1
Radiotherapy aim
Definitive 2 (9) 0 (0) 0 (0)
Salvage 20 (91) 13 (100) 4 (100)
Values are presented as n (%) unless otherwise indicated.
HT, helical tomotherapy; VMAT, volumetric-modulated arc therapy; 
ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; 
HCV, hepatitis C virus; CTP, Child–Pugh score; UICC, Union for 
International Cancer Control; TACE, transarterial chemoembolization; 
TACI, transarterial chemoinfusion; RFA, radiofrequency ablation.
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AAPM Task Group report 101: i) ≥700 mL of remaining 
normal liver should receive ≤15 Gy; ii) maximum dose 
(Dmax) to bowel, duodenum, and stomach, <24 Gy; iii) Dmax 
to spinal cord, <18 Gy; iv) ≥67% of each kidney should re-
ceive <15 Gy, and V15 should be <35%.
23 
In T group, planning CT images and all contours were 
transferred to a Tomotherapy Treatment Planning System 
(Accuray, Sunnyvale, CA, USA), enabling inverse helical 
IMRT treatment planning at 6 MV. Beamlet calculation pa-
rameters were: field width, 5 cm; pitch, 0.123; fine resolution 
mode.  
In V group, an Elekta VERSA accelerator with 10-MV flat-
tening filter free photons was used to plan treatment for plan-
ning CT and all contours. Raystation (RaySearch Laborato-
ries, Stockholm, Sweden) was used for VMAT planning. A 
1-arc arrangement was used to adapt the locations of tumor 
and normal tissues. Some arc portions were blocked to mini-
mize doses to normal structures. 
In C group, planning CT images and all contours were 
transferred to the MultiPlan CyberKnife treatment planning 
system (Accuray). The Synchrony system (Accuray) was used 
for real-time tumor targeting and Cyberknife planning. Sev-
eral light-emitting diodes (LEDs) were placed on the patient’s 
chest wall and tracked by wall-mounted cameras in the treat-
ment room. Throughout the procedure, Synchrony motion-
tracking software correlated external body surface movement 
with internal tumor fiducial movement to follow and adjust 
for tumor motion. At our institution, <3 sets of internal fidu-
cial data were entered before treatment.
On each treatment day, all patients underwent on-board 
mega-voltage CT (MVCT) or kilo-voltage CT (kVCT) for 
image-guidance (MVCT in HT SBRT; kVCT in VMAT or 
Cyberknife SBRT) before each fraction. Whole-liver MVCT/
kVCTs were registered with planning kVCT, while ensuring 
exact matching of tumor-containing hepatic segments. 
 
3. Dosimetric evaluation parameters
Each plan PTV was compared regarding dose conformity 
and homogeneity. Conformity evaluation used the compo-
Table 2. Comparison of dosimetric factors 
Characteristics HT (n=22) VMAT (n=13) Cyberknife (n = 4) P-value
ITV volume (mL) 36.0±22.8 37.3±35.5 43.3±33.3 0.720
PTV volume (mL) 87.6±39.2 85.8±69.7 79.0±54.0 0.601
Remained normal liver volume (mL) 1,309.1±274.6 1240.9±185.5 1,183.6±489.6 0.718
PTV D99% (Gy) 52.4±5.5 52.5±5.0 50.7±7.1 0.536
PTV D95% (Gy) 54.5±3.2 55.3±1.7 53.8±6.8 0.872
PTV D90% (Gy) 55.9±2.4 56.4±1.1 55.8±6.6 0.959
CI 1.0±0.2 0.7±0.2 0.8±0.2 0.097
nCI 1.3±0.4 1.4±0.6 1.4±0.4 0.234
HI 1.1±0.0 1.1±0.0 1.3±0.0 0.002
Remained normal liver Dmean (Gy) 10.5±2.0 10.3±2.6 10.0±3.6 0.989
Stomach D0.03cc (Gy) 12.7±6.2 12.4±3.9 12.5±7.8 0.967
Stomach D2cc (Gy) 10.8±5.3 10.2±3.5 10.1±6.3 0.934
Duodenum D0.03cc (Gy) 6.6±6.9 5.3±4.4 7.2±7.0 0.778
Duodenum D2cc (Gy) 4.2±4.9 2.9±2.8 5.4±6.3 0.848
MU 4,338.8±548.9 3,223.8±838.7 8,627.3±3,349.3 <0.0001
Treatment time (sec) 656.6±73.7 100.2±26.1 3,015.0±447.3 <0.0001
Values are presented as mean ± SD unless otherwise indicated.
HT, helical tomotherapy; VMAT, volumetric-modulated arc therapy; ITV, internal target volume; PTV, planning target volume; CI, conformity index; HI, 
homogeneity index; MU, monitor unit.
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nents of corresponding target volume coverage by the pre-
scribed dose (D99%, D95%, D90% for PTV) and conformity index 
(CI). CI and homogeneity index (HI) were defined as fol-
lows24:
CI = VRI/TV, HI = Imax/RI,
where VRI is the prescribed dose volume for PTV, TV is the 
total PTV, Imax is the maximum dose, and RI is the prescribed 
dose for PTV. We also calculated a normalized conformity 
index (nCI) to more accurately analyze conformity in each 
plan.25
nCI = (VRI/TV) * (100/PTV VRI),
where PTV VRI is the percentage of PTV covered by the 
prescribed isodose line.
OARs were analyzed using mean doses (Dmean) or doses to 
0.03 cc and 2 cc (D0.03cc, D2cc, respectively).
4. Statistical analysis
 
The benefit for each treatment group was assessed sepa-
rately. Data from all plans were compared with the non-para-
metric Kruskal–Wallis test and Mann–Whitney test (SPSS 
15.0; SPSS Inc., Chicago, IL, USA). Statistical significance was 
set at a P  value ≤ 0.05. 
RESULTS 
1. Target coverage, conformity, and heterogeneity 
The average ITVs (GTVs in group 3) were 36.0 mL, 37.3 
mL, and 43.3 mL in T group, V group, and C group, respec-
tively. The corresponding average PTVs were 87.6 mL, 85.8 
mL, and 79.0 mL, respectively. There were no statistically sig-
nificant differences among modalities in the maximum tu-
mor diameter, ITV, PTV, and remaining normal liver vol-
ume. No statistically significant differences were found in the 
PTV D99%, D95%, and D90% (P=0.462, 0.834, and 0.953, respec-
tively).  
In a conformity analysis, CI was better with HT than with 
Cyberknife (P=0.048) and VMAT (P=0.130). Cyberknife had 
the worst nCI, although this difference was not significant 
(P=0.097). The respective average CI and nCI were 1.0 and 
1.3 with HT, 0.7 and 1.4 with VMAT, and 0.8 and 1.4 with 
Cyberknife. Cyberknife had a significantly worse HI (mean 
1.3, range 1.30–1.37) than other plans (P=0.001). The VMAT 
and HT plan HIs did not significantly differ (Table 2).
2. Organ-at-risk dose sparing
All plans achieved our institution’s dose constraints for 
critical organs. Stomach and duodenum D0.03cc and D2cc and 
remaining normal liver Dmean did not significantly differ 
among modalities (Table 2).
3. Patient model plan comparison
For dosimetric comparison of modalities, we performed 4 
different radiotherapy plans for 1 patient: Cyberknife, HT, 
and VMAT with ABC or abdominal compressor (Fig. 1). A 
59-year-old male with cT3N0M0-stage disease received 60 Gy 
SBRT/4 fractions for residual tumor after TACE. All confor-
mal and homogenous SBRT plans achieved OAR constraints. 
With Cyberknife, a high-dose region (≥70 Gy) exceeding the 
prescribed dose (60 Gy) was observed. Superior homogeneity 
A B C D
Figure 1. Dose distributions in the axial plane with (A) cyberknife, (B) volumetric modulated arc therapy (VMAT) using active breathing control, (C) 
helical tomotherapy, and (D) conventional VMAT using abdominal compressor during the same computed tomography session (1 patient).
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and conformity were achieved with VMAT, and a more con-
formal plan and small PTV margin were available when using 
ABC. PTV coverage and conformity were superior with HT 
vs. other plans. To summarize this dosimetric comparison, i) 
PTV coverage: HT > VMAT = VMAT using ABC > Cy-
berknife, ii) OAR dose: Cyberknife > HT > VMAT = VMAT 
using ABC, iii) Conformity: HT > VMAT using ABC > 
VMAT > Cyberknife, and iv) Homogeneity: VMAT = VMAT 
using ABC = HT > Cyberknife. Additional dosimetric data 
are available in Supplementary Table 1.
4. Monitor unit and delivery time
The average total monitor unit (MU) values were 4472.0, 
3161.7, and 8083.5 for HT, VMAT, and Cyberknife, respec-
tively. Compared to HT (P<0.0001) or Cyberknife (P=0.002), 
VMAT yielded a significantly reduced MU. Mean treatment 
delivery times (beam-on times) were 698.6, 93, and 3030 sec-
onds in the T, V, and C groups, respectively. Compared to 
HT (P<0.0001) or Cyberknife (P=0.001), VMAT required the 
shortest beam-on time. 
5. Clinical benefit
Thirty-six of 39 patients had a previous TACE/TACI histo-
ry involving radioopaque lipiodol deposition in the tumor 
area that might act as a good internal fiducial marker. For 
VMAT and Cyberknife, high-resolution kVCT was acquired 
immediately before treatment, and well-traced residual lipi-
odol increased the ease, speed, and accuracy of treatment set-
up. However, lipiodols could not be visualized or traced as an 
internal marker using MVCT in HT SBRT. The recurrence-
free survival rates from the start date of radiotherapy were 
92% and 89% at 1-year and 2-year, respectively. The overall 
survival rates from the start date of radiotherapy were 95% 
and 80% at 1-year and 2-year, respectively. There was no ra-
diation-toxicity until last follow-up.
6. Patient compliance
For each modality, we analyzed compliance with treatment 
time, need for hospital admission or any invasive procedure, 
and treatment period (Table 3). Cyberknife SBRT required 
the longest time at 50–60 minutes, whereas VMAT SBRT 
only required 1–2 minutes; HT SBRT had an intermediate 
time. Regarding hospital admission or invasive procedures, 
Cyberknife SBRT required an invasive pre-treatment proce-
dure to insert external fiducials; accordingly, patients were 
admitted and observed for ≥1 day to monitor for acute com-
plications. HT or VMAT SBRT did not require complex pro-
cedures. Because VMAT could use kVCT with residual lipi-
odol as an internal marker, neither fiducial markers nor a 
long preparation time were required. However, ABC system 
application reduced compliance because patients required in-
tensive training in regular breathing over a long period, thus 
increasing the total treatment time. The total treatment time 
including kVCT and preperation before breath holding was 
approximately 10–15 minutes. Prior to Cyberknife SBRT, an 
approximately 3-week treatment period was needed because 
an interval of ≥1 week after fiducial insertion was needed 
before planning CT to prevent any possible dislocation. HT 
and VMAT required only a 2-week preparation.  
DISCUSSION 
Herein, we compared three different SBRT modalities to 
determine the appropriate choice for HCC. VMAT SBRT re-
quired the shortest treatment time and could exploit residual 
lipiodol as an internal fiducial. HT SBRT had a favorable do-
simetric outcome and the best conformity. Although Cy-
berknife SBRT could utilize a synchrony system for real-time 
Table 3. Comparison of patient compliance 
Characteristics HT VMAT Cyberknife
Treatment time  
(per 1 fraction, min)
8-15 1-2* 50-60
Need for admission to 
hospital
Necessary
Need for any invasive 
procedure
Necessary
Treatment period (weeks) 2 2 3
HT, helical tomotherapy; VMAT, volumetric arc-modulated treatment.
*Only in cases without an active breathing control device for respiration 
control.
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tumor targeting, it required the longest treatment time and 
invasive pretreatment procedures, thus causing the worst 
compliance, and was possible only in a few selected patients. 
Since its development to treat intracranial malignancies, 
SBRT has been extended to treat extracranial malignancies. 
SBRT for liver tumors was introduced in the early 1990s.26 
Liver SBRT is cumbersome because it requires accurate pa-
tient repositioning, target localization, and control of breath-
ing-related motion and confers a toxicity risk of small bowel 
including duodenum. Technological advances have allowed 
radiation delivery to small liver tumors while reducing the 
risk of normal organ toxicities. Currently, most studies of 
SBRT are retrospective, involving small cohorts with different 
histological types and high local control rates (70–90% at 1–2 
years).9-16 Several studies noted dose-response relationships 
for liver SBRT,20,27,28 and recent prospective series demon-
strated favorable outcomes.17-20 In most series with a salvage 
aim, inclusion of large tumors or heavily pretreated patients 
with repeated recurrences greatly worsened the outcomes. In 
a naïve series, however, SBRT yielded 3-year local control rate 
of 92% and a 3-year overall survival rate of 73%, comparable 
to outcomes following surgery or percutaneous ablation.29 
SBRT, however, is not yet the “standard of choice” in guide-
lines for early-stage HCC because previous phase III trials 
lacked comparisons with other local therapies. 
Currently, SBRT is indicated as a second or salvage option 
when other options, including TACE and RFA, are not appli-
cable, rather than a first option.7,8 In our study, all but 2 pa-
tients received salvage SBRT after other treatments failed. 
This unique situation requires clinical consideration. Tumors 
in the liver dome are not indicated for RFA, given the diffi-
culty of sono-guided tumor targeting under a poor sono-
graphic visual field. Post-RFA failures are also frequent in the 
S1 region, especially the porta hepatis because of the high risk 
of complication or multivascular tumor supply. For the same 
reasons, fiducial insertion would be difficult in these tumors, 
and Cyberknife SBRT is not a good option. In our study, C 
group tumors were located in S2, S3, S4, or S7/8 (not liver 
dome). In V and T groups, 13 tumors (V group: 6/13, T 
group: 7/22) were located in S8, and 6 (V group: 3/13, T 
group: 3/22) were in S1. Cyberknife SBRT could not easily be 
performed as initially planned even in 4 selected C group tu-
mors; although we attempted to insert at least 3 functional fi-
ducials, successful fiducial geometry was achieved in only 2 
patients. As an experienced interventional radiologist per-
formed fiducial insertion, Cyberknife SBRT should be con-
sidered only in highly selected tumors available for exact fi-
ducial insertion after a multidisciplinary approach. This 
limitation did not exist for VMAT or HT SBRT. Further-
more, radio-opaque lipiodol can be used as an internal fidu-
cial tumor marker advantageously during VMAT SBRT. 
Although SBRT using 3D-CRT incorporates multiple 
beams with coplanar and noncoplanar arrangements, inverse 
optimized IMRT plans were found to be dosimetrically supe-
rior to 3D-CRT at the expense of increased beam utilization 
and treatment time.30 Treatment with VMAT, an IMRT de-
livery modality, can be completed in <2 minutes with a gan-
try continuously rotating around patients and variable instan-
taneous dose rate, MLC leaf positions, and gantry rotational 
speed for dose distribution optimization; this shorter overall 
treatment time improves patient compliance and feasibility of 
breathing-holding maneuvers (e.g., ABC).31-33 High-resolu-
tion kVCT could also correct possible interfractional VMAT 
errors. Several reports involving diverse diseases have demon-
strated the superiority of VMAT SBRT after dosimetric inter-
modality comparisons. Qui et al.22 demonstrated some ad-
vantages of VMAT-based SBRT over conventional IMRT-
based SBRT for liver tumors, including substantially reduced 
delivery time (22.2%) and concomitantly reduced total MU 
required for delivery (29.2%). Kannarunimit et al.21 com-
pared 3 SBRT techniques (robotic radiosurgery, VMAT, and 
HT) and suggested guidelines for central lung lesion treat-
ment. All techniques provided similar coverage and confor-
mity, with subtle differences according to the PTV-OAR 
overlap degree or PTV size. However, to our knowledge, no 
study has compared VMAT with modern techniques, includ-
ing Cyberknife or HT, for primary HCC.     
Our study has some limitation, such as the small sample size 
for each modality and the imbalanced patient numbers among 
modalities related to the timing of device introduction in our 
institution. Second, although our experiences with VMAT and 
HT were sufficient, our experience with Cyberknife remains 
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incomplete. Third, dosimetric comparison might have been 
limited by the failure to compare different plans for the same 
patients. However, liver tumors that satisfy criteria for SBRT 
are nearly identical in shape, size, or target location. Thus, our 
dosimetric comparisons were reasonable, as confirmed by our 
additional dosimetric analysis of 4 plans for a single patient 
(Fig. 1). Our data were obtained at a single institution with the 
same experienced clinician and dosimetrist. 
In conclusion, all 3 modalities yielded competent dosimet-
ric planning. For salvage SBRT after TACE failure (the major-
ity of SBRT indications), VMAT can suitably use residual lipi-
odol as an internal fiducial and yielded the best patient 
compliance with the short treatment time. HT SBRT can be 
considered for multiple or irregular targets. Cyberknife SBRT 
can be recommended for highly selected patients with good 
performance and availability of sono-guided fiducial inser-
tion. Our results facilitate optimal modality selection for liver 
SBRT depending on clinical situations. We believe this is the 
first study to compare 3 different SBRT modalities for HCC 
and to suggest valuable modality selection guidelines. 
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